Syntr Health Technologies has been granted clearance from the US FDA (Food and Drug Administration) for their SyntrFuge System for surgical use when transferring a patient’s adipose (fat) tissue. Syntr Health Technologies, a medical device company that focuses on the processing of autologous adipose tissue, aims for their SyntrFuge System to be used in specialties including arthroscopic, gastrointestinal, gynecological, laparoscopic, neurosurgery, orthopedic, thoracic, urological, and plastic and reconstructive surgeries. The SyntrFuge System uniquely concentrates fat tissue as it maintains the cell composition and viability, two aspects which are crucial for ensuring the proper natural function of the adipose tissue in a person’s body. Together with today’s announcement, Syntr have also listed their SyntrFPU 360 device, a fundamental accessory for the SyntrFuge System, with the FDA.
Read more here.